SoftBank Shares Fall After $10 Billion OpenAI Investment 
Coinbase, Circle Stocks Slide as Bank Group Sues OCC Over Crypto Charters 
MSTR Stock Rises 3% as Strategy Challenges MSCI Bitcoin Stance 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
Goldman Sachs Names CATL, Zenergy Top China Battery Picks 
Disney Plans TV Restructuring With Hundreds of Layoffs 
Zcash Awards $8 Million in Grants After Orchard Bug Crisis 
Circle Urges EU to Revise MiCA Stablecoin Rules 
Trump Praises Boeing 737 Max After Flydubai Crash Attempt 
Flydubai FZ1073 Co-Pilot Accused of Terror Attack 
Evernorth Set for Nasdaq Debut With 473 Million XRP Treasury 
Malaysia Aviation Group to Buy Airbus SAE Unit 
Bank of America Sees EUR/USD at 1.15 by Year-End 
Citi Raises Bitcoin Price Target to $113,000 on ETF Optimism 
Amazon Eyes $8 Billion Nvidia Chip Spinoff to Fund AI Expansion 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
Ripple Locks 700 Million XRP Back in Escrow After October Release 
Add as a preferred source on Google
GAITHERSBURG, Md., Feb. 20, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its fourth quarter and full year 2016 financial and operating results following the close of U.S. financial markets on Monday, February 27, 2017.
Conference call details are as follows:
| Date: | Monday, February 27, 2017 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 61206704 | |
| Webcast: | www.novavax.com, “Investors”/ “Events” | |
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, February 27, 2017, until midnight March 3, 2017 | |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 61206704 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until April 30, 2017 | |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Westwicke Partners John Woolford [email protected] 443-213-0506 Media Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] 212-845-4271
